BioSpace News Archive

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) Application to begin a Phase 1 clinical program of its immunotherapeutic candidate, NL-201.

Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative therapies, today announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM)

Blacksmith Medicines, Inc. (Blacksmith), a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced today that it has secured seed funding and has entered into a research collaboration with Eli Lilly and Company (Lilly).

Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will present a webcasted company overview at the 39th Annual J.P. Morgan Healthcare Conference

- Under the partnership, PACT Pharma will provide the company with insight into autologous NeoTCR manufacturing workflows to help identify product-market fit and secure early access to the technology for an undisclosed amount - PACT Pharma is the second organization and first industry partner to join the program following Fred Hutchinson Cancer Research Center

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2021 on Wednesday, January 27, after the market closes.

Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total score compared to placebo at Week 2 in all tested doses, with a dose-response trend. MADRS placebo-subtracted differences were -5.9 (95%

Enzychem Lifesciences (KOSDAQ: 183490), announced today that Ki Young Sohn, Chief Executive Officer & Chairman, will be presenting a company overview and participating in virtual one-on-one meetings at Biotech Showcase Digital , held January 11-15, 2021 .

Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today received formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Listing Rule 5550(a)(2). Previously, on December 27, 2019, Nasdaq had notified the Company that its common stock failed

Varian (NYSE: VAR) today announced its first quarter fiscal year 2021 earnings release date. The Company will report results for the first quarter of fiscal year 2021 after market close on Tuesday, January 26, 2021 . In light of the pending transaction with Siemens Healthineers, Varian will not be hosting a conference ca